FIELD: medicine, pharmacy. SUBSTANCE: pharmaceutical composition has antibody raised to interkeukin-6 receptors and can be used for preparing preparations for treatment of patients with diseases caused by blood state damage, immunological disturbances, tumors and other diseases caused by formation of IL-6. In part, composition can be used for prophylaxis and treatment of patients with plasmacytosis, hyperimmunoglobulinemia, anemia, nephritis, cachexia, rheumatism, Kastlman's disease, mesangial proliferating nephritis. Monoclonal antibody, antibody PM-1, chimeric antibody, human antibody, modified human antibody PM-1 can be used as an antibody. Composition shows effectiveness against multitude of diseases caused by formation of IL-6 but it does not shows any effect at normal level of IL-6. EFFECT: enhanced effectiveness of composition. 14 cl, 18 dwg, 4 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| DRUGS AGAINST CHRONIC RHEUMATIC ARTHRITIS CONTAINING ANTAGONIST OF IL-6 AS EFFECTIVE COMPONENT | 1995 |
|
RU2147443C1 |
| PROPHYLACTIC OR THERAPEUTIC AGENT FOR TREATING INFLAMMATORY INTESTINAL DISEASES CONTAINING IL-6 ANTAGONIST AS AN ACTIVE INGREDIENT | 1999 |
|
RU2195960C2 |
| PROPHYLACTIC DRUG FOR VASCULITIS | 2004 |
|
RU2379054C2 |
| THERAPEUTIC AGENT FOR MESOTHELIOMA | 2004 |
|
RU2554942C2 |
| THERAPEUTIC AGENT FOR MESOTHELIOMA | 2004 |
|
RU2392967C2 |
| METHOD OF TREATING INTERLEUKIN-6-DEPENDENT DISEASES | 2004 |
|
RU2509574C2 |
| THERAPEUTIC AGENT USED FOR GRAFT-VERSUS-HOST DISEASE, CONTAINING INTERLEUKIN-6 RECEPTOR INHIBITOR AS ACTIVE INGREDIENT | 2008 |
|
RU2490025C2 |
| AGENT FOR CARDIOPATHY | 2006 |
|
RU2450830C2 |
| CHRONIC REJECTION INHIBITOR | 2008 |
|
RU2450829C2 |
| AGENT USED IN TREATMENT OF LYMPHATIC TISSUE TUMORS | 1998 |
|
RU2177805C2 |
